Abstract: Pharmaceutical compositions containing tetrathiomolybdate (TTM) are disclosed. Pharmaceutical compositions and formulations that contain TTM along with other co-drugs, such as diethylcarbamazine (DEC) and astaxanthin (ATX), are also disclosed. Formulations include a delayed release oral form that releases the TTM in the gastrointestinal tract after the oral form passes the stomach, and an enteric oral form that is not a delayed release form are disclosed. Methods of treating cancer, treating cancer patients as an adjuvant therapy, and treating pulmonary arterial hypertension by administering the pharmaceutical compositions are further disclosed.

Abstract: A method of treating COPD, Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis and PAH in a patient. One embodiment includes administering a vasodilator prostacyclin analogue, such as Beraprost or Iloprost, separately or together with a form of Diethylcarbamazine or Zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. Diethylcarbamazine/Zileuton is inhaled into the lung or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces the progression of the disease, reduces life-threatening exacerbations, and improves the quality of life. The treatment is also for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD including pulmonary hypertension and intravascular inflammation and bronchiectasis.

Abstract: A method of treating a Corona Virus, e.g., COVID 19, Influenza and ARDS, is provided. A copper chelator including a tetrathiomolybdate salt is administered with a 5-lipoxygenase enzyme inhibitor, e.g., Diethylcarbamazine or Zileuton. Baicalin, Bufalin, Quercetin, Curcumin, inhibitors of NF-kappaB, the Applied Therapeutics Aldose Reductase inhibitor AT-001, Sulforaphane or Fluvoxamine can be additional drugs. This is an intervention treatment of a Corona Virus, e.g., COVID 19, ideally in the second phase of the disease, in the Pulmonary Phase, preferably prior to the Hyper-Inflammation Phase, as a preventive therapy to reduce the need for a ventilator and increase the survival of hospitalized patients. The two-drug treatment combination aims at preventing ARDS and other organ damage caused by COVID 19 infection by targeting the intravascular disease component.

Abstract: A method of treating severe forms of PH, including PAH, in a patient is provided. The method includes administering at least one copper chelator comprising a tetrathiomolybdate (TTM) salt. The method may further include administering at least one active agent that enhances treatment such as methotrexate, inhibitors of the 5-lipoxygenase enzyme (5-LO), rituximab, baicalin, inhibitors of immune checkpoints CTLA-4, PD-1 and PDL-1, bufalin, quercetin, curcumin, integrins, inhibitors of NF-kappaB, and focal adhesion kinase inhibitors. Also provided is a composition including the TTM salt and the at least one active agent.

Abstract: A railway hopper car comprises one or more gates, which have a durable, abrasion-resistant, low-friction coating applied to the upper, load-contacting surface thereof to reduce breakaway opening torque. The railway hopper car is particularly useful in handling heavy loads of bulk materials which have high densities and which compact under load, such as soya meal and hydrated alumina. The preferred coating use on the gate is a polymeric powder paint coating having high impact resistance, as well as high abrasion resistance, at the temperature extremes that may be experienced in the harsh operating environments typically encountered by railway hopper cars. The preferred coating is a food grade material suitable for use in contact with bulk agricultural commodities.